Key facts
- Pfizer said Blackstone would provide up to $1.5 billion through 2028, according to Reuters.
- The funding is for development of an experimental monthly obesity treatment Pfizer did not name.
Pfizer said on November 11, 2026 that Blackstone would provide up to $1.5 billion through 2028 to help fund development of its experimental monthly obesity treatment, according to a Reuters report.
The company did not name the drug, its development stage or the terms attached to the funding in the account. The money is committed through 2028 and is described as funding for development rather than a purchase of any asset.